Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : COVID-19 drug helps boost 2nd-quarter results as HIV sales dip

07/29/2021 | 05:05pm EDT
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

July 29 (Reuters) - Gilead Sciences Inc on Thursday posted a higher-than-expected second-quarter profit, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors.

Sales of HIV medicines, which have stalled during the coronavirus pandemic, fell 2% to $3.9 billion.

Gilead Chief Commercial Officer Johanna Mercier on a conference call with analysts said HIV sales in Europe have begun to recover, but U.S. demand has been slower. "It is clear that it will take several quarters for treatment to return to pre-pandemic levels," she said.

Gilead shares, which closed at $69.83, were down more than 2% in extended trading.

Gilead reported adjusted quarterly earnings of $1.87 per share, beating Wall Street expectations by 12 cents.

The biotechnology company's total revenue for the quarter rose 21% from a year earlier to $6.2 billion, slightly higher than the average analyst estimate of $6.07 billion, according to Refinitiv data.

The results were "driven by in-line performance of their core products and strength in Veklury, demonstrating the ability of their portfolio mix to hedge against any COVID-related headwinds. Oncology and hepatitis C businesses were encouragingly solid," RBC Capital Markets analyst Brian Abrahams said in a research note.

Sales of Veklury, known chemically as remdesivir, totaled $829 million for the quarter, easily topping Wall Street estimates of $675 million.

Gilead said Veklury sales would continue to be subject to uncertainty since they are tightly linked to COVID-19 hospitalization rates. The company also said it was no longer pursuing development of an inhaled version of the drug for COVID-19.

Chief Executive Daniel O'Day said Veklury, given intravenously to hospitalized patients, is effective against all known variants of the coronavirus, adding that the company continues to develop other pipeline products for treating COVID-19 outside of a hospital setting.

Sales of Gilead's hepatitis C drugs bounced back in the quarter, rising 23% to $549 million.

For full-year 2021, Gilead narrowed its forecast for adjusted earnings per share to $6.90 to $7.25 from its prior projection of $6.75 to $7.45.

The company said it now expects product sales for the year of $24.4 billion to $25 billion, compared with a previous estimate of $23.7 billion to $25.1 billion. (Reporting By Deena Beasley Editing by Bill Berkrot)


© Reuters 2021
All news about GILEAD SCIENCES, INC.
09/17GILEAD SCIENCES : Trodelvy Significantly Improved Quality of Life Over Standard ..
AQ
09/17GILEAD SCIENCES : New Data Demonstrate Trodelvy Survival Benefit in Metastatic T..
AQ
09/16GRITSTONE BIO : Oncology Places 5 Million Shares for $55 Million -- Stock Down 5..
MT
09/16VC DAILY : Venture Capitalists Push Back Against Drug-Pricing Bill
DJ
09/16GILEAD SCIENCES' : Late-Stage Study Shows Breast Cancer Drug May Improve Overall..
MT
09/16GILEAD SCIENCES : Trodelvy® Significantly Improved Quality of Life Over Standard..
BU
09/16GILEAD SCIENCES : New Data Demonstrate Trodelvy® Survival Benefit in Metastatic ..
BU
09/16Gilead Sciences, Inc Announces New Data Demonstrate Trodelvy Survival Benefit..
CI
09/16Gilead Says Trodelvy Improved Quality of Life in Breast Cancer in Study
DJ
09/14GILEAD SCIENCES, INC. : Ex-dividend day for
FA
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 24 999 M - -
Net income 2021 6 525 M - -
Net Debt 2021 23 112 M - -
P/E ratio 2021 14,2x
Yield 2021 3,95%
Capitalization 89 785 M 89 785 M -
EV / Sales 2021 4,52x
EV / Sales 2022 4,45x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 71,61 $
Average target price 76,38 $
Spread / Average Target 6,66%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850
BEIGENE, LTD.56.02%37 507